This company is focused on developing innovative cell and gene therapies. Their representative pipelines include KLS-2031, which is in Phase 1/2a clinical trial for the treatment of neuropathic pain, and KLS-3021, which is in preclinical study as an oncolytic viral therapy.
| Contact Details | HQ / R&D Center One & Only Tower, 110, Magokdong-ro, Gangseo-gu, SeoulMain office+82-2-3677-4150 |
|---|
